NCT05548296 2026-03-24
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Acrivon Therapeutics
Phase 2 Recruiting
Clinical Trials
3 trialsNCT03414047 2022-08-19
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02735980 2020-03-17
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed